Fig 1: IL-18BP protein levels increase after immunotherapy in nonresponding patients with RCC.(A) Kaplan-Meier curves of overall survival of patients with RCC after ICIs by IL-18BP protein expression, dichotomized by median qIF levels. (B) IL-18BP protein levels assessed by qIF in the same RCC patient cohort as A, before and after ICIs, in ICI responders/nonresponders. (C) Circulating plasma levels of IL-18BP, as assessed by ELISA, from patient-matched samples before and after ipi + nivo treatment in a different RCC patient cohort from A and B. (D) Circulating plasma levels of IL-18BP from patient-matched samples before- and during ipi + nivo treatment, separated by treatment response. (E) The ratio of post/pretreatment IL-18BP plasma levels by treatment response. (F) The directional change of IL-18BP plasma levels after treatment by response. (G) Kaplan-Meier curves of progression-free survival (PFS) after ipi + nivo by directional change in circulating IL-18BP levels after treatment, in the same RCC cohort as in C–F. Statistical testing was performed using Mann-Whitney U test (B and E), Wilcoxon matched-pairs signed rank test (C and D), and Fisher’s exact test (F). Due to small samples sizes, formal statistical testing was not conducted on G, and the analysis should be viewed as hypothesis generating. *P < 0.05; **P < 0.01.
Fig 2: IL18BP and IL18R1 are expressed at high levels in ccRCC and elevated IL18BP is associated with cytokine and T cell activation and worse survival.(A–C) IL18R1 and IL18BP expression from TCGA PanCancer Atlas for all tumors (ccRCC indicated with red asterisk) (A), RCC histologic subtypes (B), and for ccRCC (C), by stage. (D) Kaplan-Meier survival curves based on IL18BP expression in ccRCC, dichotomized by median expression. (E) Volcano plot of transcripts enriched with high versus low IL18BP expression in ccRCC (log2 fold-change thresholds of 1 and –1; P value threshold of 1 × 10–6). (F) The top gene sets from enrichment analysis of transcripts enriched with high IL18BP expression. For B and C, statistical testing was performed using Kruskal-Wallis test with Dunn’s correction for multiple comparisons. **P < 0.01; ***P < 0.001; ****P < 0.0001.
Supplier Page from Abcam for Human IL-18BP ELISA Kit